L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial

Abstract Rapid vascular recovery is a key feature preceding glioblastoma (GBM) recurrence after radiotherapy (RT). We performed spatial expression analyses, providing a rationale for dual inhibition of two non-redundant, spatially distinct acting factors, CXCL12 and VEGF. Subsequently, we expanded a...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Frank A. Giordano, Julian P. Layer, Roberta Turiello, Lea L. Friker, Oriol Mirallas, Barbara E. F. Pregler, Anna-Laura Potthoff, Thomas Zeyen, Johannes Weller, Elena Sperk, Katharina Sahm, Christoph Oster, Sied Kebir, Peter Hambsch, Niklas Schäfer, Sebastian Kadzik, Mirjam Renovanz, Torsten Pietsch, Sotirios Bisdas, Juan Manuel Sepúlveda-Sánchez, Diego Gómez-Puerto, Maria Vieito, Michael Platten, Eleni Gkika, Oliver M. Grauer, Ghazaleh Tabatabai, Matthias Schneider, Martin Glas, Clemens Seidel, Ulrich Herrlinger, Michael Hölzel
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Nature Portfolio 2026-04-01
Serie:	Nature Communications
Länkar:	https://doi.org/10.1038/s41467-026-71362-7
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!